E. Berns

2.5k citations

42 papers · 2.0k indexed · h-index 23

Impact in

Cancer Research top 2%
- Cancer Genomics and Diagnostics
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Reproductive Medicine top 2%
- Ovarian cancer diagnosis and treatment

Papers in ⓘ

Cancer Research 22
- Cancer Genomics and Diagnostics 10
- Cancer, Lipids, and Metabolism 5
- Breast Cancer Treatment Studies 4
Oncology 21
- Cancer-related Molecular Pathways 12
- HER2/EGFR in Cancer Research 6

Co-authors: John A. Foekens (13 shared papers)J.G.M. Klijn (14 shared papers)Iris L. van Staveren (8 shared papers)Henk Portengen (6 shared papers)S.C. Henzen‐Logmans (7 shared papers)J.G.M. Klijn (4 shared papers)Ignace Vergote (4 shared papers)Jozien Helleman (5 shared papers)
Journals: British Journal of Cancer (11 papers)Breast Cancer Research and Treatment (5 papers)European Journal of Cancer (3 papers)Annals of Oncology (2 papers)International Journal of Gynecological Cancer (2 papers)
Partner nations: Netherlands Belgium United States

In The Last Decade

E. Berns

42 papers receiving 2.0k citations

Peers

Countries citing papers authored by E. Berns

Since Specialization

Citations

This map shows the geographic impact of E. Berns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Berns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Berns more than expected).

Fields of papers citing papers by E. Berns

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Berns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Berns. The network helps show where E. Berns may publish in the future.

Co-authors

The 25 scholars most cited alongside E. Berns, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with E. Berns Line = papers co-authored together E. Berns links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 42 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells Oncogene ·Marijn T. M. van Jaarsveld, Jozien Helleman, Antonius W.M. Boersma, Patricia F. van Kuijk, Wilfred F. J. van IJcken, Evelyn Despierre, Ignace Vergote, Ron H.J. Mathijssen, E. Berns, Jaap Verweij, Joris Pothof, Erik A.C. Wiemer	2012	180
2	c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. PubMed ·E. Berns, J.G.M. Klijn, W L van Putten, Iris L. van Staveren, Henk Portengen, John A. Foekens	1992	177
3	A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. Journal of Clinical Pathology ·P J van Diest, Peter A. van Dam, S.C. Henzen‐Logmans, E. Berns, M E van der Burg, J. Green, Ignace Vergote	1997	175
4	Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. PubMed ·E. Berns, John A. Foekens, R. van Vossen, Maxime P. Look, Peter Devilee, S.C. Henzen‐Logmans, Iris L. van Staveren, Wim L.J. van Putten, Mats Inganäs, Marion E. Meijer‐van Gelder, Cees J. Cornelisse, Cassandra J.C. Claassen, Henk Portengen, Egbert Bakker, J.G.M. Klijn	2000	162
5	Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients Annals of Oncology ·P.M.L.H. Vencken, Mieke Kriege, D. Hoogwerf, S. Beugelink, M.E.L. van der Burg, Maartje J. Hooning, E. Berns, Agnes Jager, Margriet Collée, Curt W. Burger, Caroline Seynaeve	2011	154
6	Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2) British Journal of Pharmacology ·Henry Burger, Adja Zoumaro‐Djayoon, AWM Boersma, Jozien Helleman, E. Berns, Ron H.J. Mathijssen, WJ Loos, Erik A.C. Wiemer	2010	101
7	The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer British Journal of Cancer ·Xuan Bich Trinh, Wiebren Tjalma, Peter Vermeulen, G. Van den Eynden, Ilse Van der Auwera, Steven Van Laere, Jozien Helleman, E. Berns, Luc Dirix, Peter A. van Dam	2009	95
8	Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer British Journal of Cancer ·E. Berns, IL van Staveren, MP Look, Marcel Smid, J.G.M. Klijn, JA Foekens	1998	76
9	Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2 British Journal of Cancer ·Monique Schuyer, M.E.L. van der Burg, S.C. Henzen‐Logmans, J H Fieret, J.G.M. Klijn, Maxime P. Look, J A Foekens, G. Stoter, E. Berns	2001	75
10	Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. PubMed ·E. Berns, J.G.M. Klijn, Iris L. van Staveren, Henk Portengen, John A. Foekens	1992	70
11	High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer Breast Cancer Research and Treatment ·M. P. H. M. Jansen, Esther A. Reijm, Anieta M. Sieuwerts, Kirsten Ruigrok-Ritstier, Maxime P. Look, F. Germán Rodríguez-González, Anouk A. J. Heine, John W.M. Martens, Stefan Sleijfer, John A. Foekens, E. Berns	2011	61
12	Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families European Journal of Cancer ·L.C. Verhoog, A.M.W. van den Ouweland, E. Berns, Monique M. van Veghel–Plandsoen, Iris L. van Staveren, Anja Wagner, C.C.M. Bartels, Madeleine M.A. Tilanus‐Linthorst, Peter Devilee, Caroline Seynaeve, Dicky Halley, M. F. Niermeijer, J.G.M. Klijn, Hanne Meijers‐Heijboer	2001	52
13	Prognostic factors and response to therapy in breast cancer. PubMed ·J.G.M. Klijn, E. Berns, John A. Foekens	1993	51
14	p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. Journal of Clinical Oncology ·E. Berns, J.G.M. Klijn, W L van Putten, Hans H. de Witte, Maxime P. Look, Marion E. Meijer‐van Gelder, K. Willman, Henk Portengen, T J Benraad, John A. Foekens	1998	50
15	Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy British Journal of Cancer ·Mieke Kriege, Antoinette Hollestelle, Agnes Jager, Petra E.A. Huijts, E. Berns, Anieta M. Sieuwerts, Marion E. Meijer‐van Gelder, J.M. Collée, Peter Devilee, Maartje J. Hooning, John W.M. Martens, Caroline Seynaeve	2014	49
16	The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer British Journal of Cancer ·Laureen A. Lammers, Ron H.J. Mathijssen, Teun van Gelder, Monique J. Bijl, A-J M de Graan, Caroline Seynaeve, M A van Fessem, E. Berns, Arnold G. Vulto, Ron H. N. van Schaik	2010	48
17	Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer Breast Cancer Research and Treatment ·Esther A. Reijm, Maurice P.H.M. Jansen, Kirsten Ruigrok-Ritstier, Iris L. van Staveren, Maxime P. Look, M.E. Meijer - van Gelder, Anieta M. Sieuwerts, Stefan Sleijfer, John A. Foekens, E. Berns	2010	43
18	Prognostic factors in human primary breast cancer: Comparison of c-myc and HER2/neu amplification The Journal of Steroid Biochemistry and Molecular Biology ·E. Berns, John A. Foekens, Wim L.J. van Putten, Iris L. van Staveren, Henk Portengen, W. Köning, Jan G.M. Klijn	1992	41
19	CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial Breast Cancer Research and Treatment ·Vincent O. Dezentjé, Ron H. N. van Schaik, J. M. Vletter-Bogaartz, Tahar van der Straaten, Judith A.M. Wessels, Elma Meershoek – Klein Kranenbarg, E. Berns, Caroline Seynaeve, Hein Putter, Cornelis J.�H. van de Velde, J.W.R. Nortier, Hans Gelderblom, Henk‐Jan Guchelaar	2013	39
20	Luteinizing Hormone Signaling and Breast Cancer: Polymorphisms and Age of Onset The Journal of Clinical Endocrinology & Metabolism ·Brenda L. Powell, Djura Piersma, Marlies E. Kevenaar, Iris L. van Staveren, Axel P. N. Themmen, Barry Iacopetta, E. Berns	2003	34

About E. Berns

E. Berns is a scholar working on Cancer Research, Oncology, Molecular Biology, Genetics and Reproductive Medicine, having authored 42 papers that have together received 2.0k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (12 papers), Cancer Genomics and Diagnostics (10 papers), Ovarian cancer diagnosis and treatment (9 papers), HER2/EGFR in Cancer Research (6 papers), BRCA gene mutations in cancer (6 papers), Cancer, Lipids, and Metabolism (5 papers), Estrogen and related hormone effects (5 papers) and Breast Cancer Treatment Studies (4 papers). The work is most often cited by research in Cancer Research (763 citations), Reproductive Medicine (294 citations), Oncology (921 citations), Genetics (488 citations) and Molecular Biology (1.0k citations). E. Berns has collaborated with scholars based in Netherlands, Belgium and United States. Frequent co-authors include John A. Foekens, J.G.M. Klijn, Iris L. van Staveren, Henk Portengen, S.C. Henzen‐Logmans, J.G.M. Klijn, Ignace Vergote, Jozien Helleman, Maxime P. Look and Peter A. van Dam. Their work appears in journals such as British Journal of Cancer, Breast Cancer Research and Treatment, European Journal of Cancer, Annals of Oncology and International Journal of Gynecological Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact